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diesterase 4 (PDE4). The co-crystal structure reveals a binding conﬁguration which is unique com-
pared to classical catechol PDE4 inhibitors, with boron binding to the activated water in the
bimetal center. These phenoxybenzoxaboroles can be optimized to generate submicromolar
potency enzyme inhibitors, which inhibit TNF-a, IL-2, IFN-c, IL-5 and IL-10 activities in vitro and
show safety and efﬁcacy for topical treatment of human psoriasis. They provide a valuable new
route for creating novel potent anti-PDE4 inhibitors.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The single known mechanism for removing cellular 30,50-cyclic
adenosine monophosphate (cAMP), a critical intracellular messen-
ger for regulation of immune responses, is through degradation to
AMP via the cyclic nucleotide-selective phosphodiesterase (PDE)
family of enzymes [1]. The four phosphodiesterase 4 (PDE4) en-
zymes (A/B/C/D) play a critical role in degrading cAMP in lympho-
cytes, endothelial cell, keratinocytes and smooth muscle cells [2].
As these enzymes are important regulators of inﬂammation via
this degradation, they are potential targets for therapeutic immu-
nomodulation and have been the focus of extensive drug develop-
ment programs for treatment of autoimmune diseases [3,4].
Phenoxybenzoxaboroles are novel small molecules which incorpo-
rate a boron atom into the 5-membered ring of a six-ﬁve bicyclic
molecule. These compounds have anti-inﬂammatory activity by
inhibiting PDE4 enzymes [5]. Two of the compounds discussed
here have demonstrated good safety and efﬁcacy in human clinical
trials of psoriasis. We now report on the crystal structure of a
phenoxybenzoxaborole bound to the PDE4 catalytic site and showal Societies. Published by Elsevier
uticals Inc., 1020 E. Meadow
660.
).that the phenoxybenzoxaboroles bind the PDE4 catalytic site in a
novel way, analogous to the binding of AMP. This binding is dis-
tinct from that of traditional catechol PDE4 inhibitors. We have
created phenoxybenzoxaboroles with high afﬁnities for the cata-
lytic site by combining the novel binding with traditional binding
to the adenine pocket. The new binding mode and the favorable
drug-like properties of this structural class offer promise as inhib-
itors of PDE4 for treatment of inﬂammation and autoimmune dis-
ease, as well as the possibility of targeting other metalloenzymes
for therapeutic purposes.2. Materials and methods
2.1. Reagents
All phenoxybenoxaboroles were synthesized at Anacor Pharma-
ceuticals Inc. (Palo Alto, CA) or NAEJA Pharmaceuticals (Edmonton,
Alberta, Canada) [5]. [3H]-cAMP was obtained from GE Healthcare,
fetal calf serum from MediaTech Inc. (Hearndon, VA) and phyto-
hemagglutinin (PHA) from Roche Diagnostics GmbH (Mannheim,
Germany). The FACS Array ﬂow cytometer, and BD Cytometric
Bead Array Flex Set were obtained from BD Biosciences (San Jose,
CA). All other reagents were obtained from Sigma–Aldrich (St.
Louis, MO).B.V. Open access under CC BY-NC-ND license.
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Inhibition of PDE4 subtypes were performed with enzymes
which were expressed and puriﬁed from Sf9 cells [6]. Genbank
numbers are included in Table 1. ATP substrate was used at
40 nM and assays were performed at room temperature for
30 min in duplicate. Stock solutions of compounds were prepared
at 10 mM in 100% DMSO. Final DMSO concentration was 1% or less.
Each compound was tested by performing serial half-log dilutions
at starting concentration of 10 or 30 lM. IC50 values and Hill coef-
ﬁcients (nH) were determined by non-linear regression analysis
using the four parameter logistic equation.
2.3. Enzyme kinetics
PDE4B enzymatic activity was determined using a 96-well for-
mat, essentially as described by Saldou et al. [6]. A truncated pro-
tein containing the catalytic domain of PDE4B2 (SwissProt ID is
Q07343) expressed in Escherichia coli (Proteros Biostructures, Mar-
tinsried, Germany) was used in all kinetic experiments at 30 pg/
mL. cAMP as the reaction substrate, was supplemented with
8000 cpm/lL of [3H]-cAMP. Enzyme kinetic data was obtained by
ZnSO4/Ba(OH)2 precipitation of the AMP product after reaction
quenching. The precipitate was collected by ﬁltration onto Multi-
Screen HTS, FB plates (Millipore, Billerica, MA), washed, then dried
for quantitation of radioactivity.
2.4. Protein crystallography
The DNA-sequence encoding human PDE4B (amino acids 152–
484) was ampliﬁed by PCR and cloned in the pProExHTA vector
using NcoI and XhoI restriction sites. Cloning details are included
in the Supporting information (SI). Crystallization conditions with
the ligand, statistics of data collection and processing and reﬁne-
ment statistics are detailed in the SI. The crystals belong to space
group P43212 and diffract to beyond 1.95 [A]2. Diffraction data
were collected on the X06SA beamline at the SWISS LIGHT SOURCE
(Villigen, Switzerland). Data were processed using XDS and XSCALE
[7].
2.5. Analysis of cytokine inhibition in peripheral blood mononuclear
cells
Peripheral blood mononuclear cells (PBMCs) pooled from 10 to
20 donors, were ﬁcoll-gradient puriﬁed, and stored in liquid nitro-
gen. Cells were seeded into 96-well plates at 5  105 cells/well in
RPMI 1640 with 10% heat-inactivated fetal calf serum. CompoundsTable 1
Inhibition of human phosphodiesterase 4 (PDE4) by AN2728 and AN2898 compared to Ro
Compound Structure PDE4B1 (lM) PDE4A1A (average s
AN2728 0.75 ± 0.19 0.72 ± 0.12 (0.96)
AN2898 0.24 ± 0.01 0.35 ± 0.1 (1.46)
Rolipram 0.06 ± 0.06 0.11 ± 0.09 (1.8)
Compounds were tested against PDE4 enzymes expressed and puriﬁed from Sf9 cells.
PDE4A1A: GenBank: U97584.
PDE4B1: GenBank: NM_001037341.
PDE4D2: Genbank: NM_006203.dissolved in 100% dimethyl sulfoxide (DMSO) were diluted in med-
ia to a ﬁnal DMSO concentration of <1%. Lipopolysaccharide stim-
ulation (1 lg/mL) for 24 h was used to measure TNF-a and IL-1b
production. 20 lg/mL PHA was used for 24 h to measure IL-2 and
IFN-c or for 48 h to measure IL-4, IL-5, and IL-10 production. Opti-
mal incubation times were determined in preliminary experi-
ments. Cytokines were analyzed with a FACSArray ﬂow
cytometer using BD Cytometric Bead Array Flex Sets. Data were
analyzed using the FCAP Array software (BD Biosciences) and
IC50 values were calculated using the four parameter logistic ﬁt
equation. IC50 values were expressed as averages of geometric
means ± fold variance (geometric standard deviation).3. Results
3.1. AN2728 and AN2898 inhibit the major isoforms of PDE4 in vitro
AN2728 and AN2898 demonstrated submicromolar IC50 values
(Table 1) against PDE4 isoforms A and B. AN2728 showed low
micromolar IC50 values against PDE4D2 while AN2898 showed sub-
micromolar values. AN2728 and AN2898 showed equal activity
against isoforms PDE4A1a and B1, consistent with Rolipram. They
showed 3- to 4-fold less activity against PDE4D2, whereas Rolipram
was equipotent against PDE4D2. AN2728 and AN2898 were tested
for their ability to inhibit other phosphodiesterases (Table 3). Both
compounds inhibited PDE1 and 3 with single digit micromolar IC50
values, however selectivity was 56- to 153-fold greater against
PDE4. AN2728 and AN2898 inhibited PDE7 at submicromolar lev-
els, showing an 8-fold greater selectivity for PDE4. AN2728 inhib-
ited the remaining PDEs to less than 60% at 10 lM. AN2898
inhibits PDE 5, 6, 9 and 10 to less than 60% at 10 lM and PDE8
and 11 to less than 75% at this concentration. For comparison, Rof-
lumilast showed >10 lM IC50 values for PDE1, 2, 3 and 7–11 and
inhibited PDE5A1 and PDE6 with IC50 values of 4.5 and 4.2 lM,
respectively [3]. Its IC50 value against PDE4 was 0.8 nM [3].
3.2. AN2728 and AN2898 are competitive, reversible PDE4 active site
inhibitors
AN2898 acted as a substrate competitive inhibitor of PDE4B
(Fig. 1) as demonstrated by the lack of change in Vmax, and increase
in the apparent Km with increasing inhibitor concentrations. A Ki
value of 65 ± 9.8 nM for the AN2898–PDE4B interaction was deter-
mined from the Lineweaver–Burk plot. A similar analysis was per-
formed with AN2728, yielding a Ki of 173 ± 26 nM (Fig. S1,
Supporting information).lipram in three separate experiments.
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Fig. 1. Rate of PDE4B (catalytic domain, expressed in E. coli, Proterus Biostructures) inactivation by AN2898. (A) PDE4B rate at various AN2898 concentrations; (B)
Lineweaver–Burk plot.
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reversible, the enzyme was ﬁrst pre-incubated with 2 lM AN2898
for 20 min. Enzyme-inhibitor complexes were then diluted
200-fold and reaction rates were immediately measured. The
AN2898–PDE4B inhibitor complex was reversible, as 86% enzyme
activitywas immediately recovered after complete PDE4 inhibition.
3.3. Crystal structure demonstrates unique binding for
phenoxybenzoxaboroles
AN2898 was co-crystallized with the catalytic domain of PDE4B
and was shown to bind at the active site of the enzyme, consistent
with the kinetic studies. As shown in Fig. 2, the water molecule
held and activated by the two metal ions, zinc and magnesium,
is coordinated to the boron atom of AN2898, so that the boron
adopts a tetrahedral form. The fused benzo group interacts with
the hydrophobic sidechains of Met347 and Leu393, while the
3,4-dicyanophenoxy ring resides at the entrance of a deep hydro-
phobic pocket, stacking with the aromatic ring of Phe446. Superpo-
sition of the crystal structure of AN2898 with that of AMP [8] at the
active site of PDE4B revealed that the tetrahedral boron group from
AN2898 overlaps the phosphate group from AMP, allowing similar
interactions with the metal ions (Fig. 2).His 238 Asn 395 
Phe 446 Leu 393 Zn++His 274 
Met 431 
Asp 275 
Mg++
Met 247 
Fig. 2. Crystal structure of AN2898 (cyan), bound at the active site of PDE4B
catalytic domain, is superimposed onto that of AMP (white). The crystal structure of
AMP complexed with PDE4 was obtained from a protein data bank, 1PTW. Color
code: blue for carbon in AN2898/PDE4B structure and white for AMP/PDE4B
structure, red for oxygen, and dark blue for nitrogen atoms.AN2898 binds to the PDE4 active site in a unique mode, distinct
from that of other catechol-based PDE4 inhibitors (Fig. S2, Support-
ing information) Instead of fully utilizing the deep pocket occupied
by the adenine ring from AMP and the catechol moiety from Roﬂu-
milast, where H-bonding interactions with the side chain of
Gln443 are observed, the anchor point for AN2898 is the extensive
metal chelating interactions of the oxaborole moiety. Therefore im-
proved afﬁnity could be obtained by installing a side chain onto
AN2898 to probe the adenine pocket which is mainly formed by
the sidechains of Phe446, Ile410 and Gln443. Our second genera-
tion PDE4 inhibitors, exempliﬁed by AN4800, were designed to uti-
lize both the bimetal site and the adenine pocket as shown in the
docking model of AN4800 (Fig. 3). The ﬂexible 2-acetoxyethoxy
group of AN4800 is shown in the model to ﬁll in the adenine pocket
and picks up a signature hydrogen bond with Gln443 while the
main scaffold retains the binding mode of AN2898. When
AN4800 was tested for inhibition of the semi-puriﬁed PDE4 en-
zyme, it demonstrated an IC50 of 0.70 nM, approximately a 100-
fold improvement over AN2898 (60 nM), demonstrating that
highly potent benzoxaborole PDE4 inhibitors can be obtained by
combining the interactions with the bimetal site and the adenineAsp 275 
Tyr 233 
Ile 410
Phe 414
Gln 443 
Phe 446 
Compound Structure PDE4 IC50 (µM)
AN4800 0.00070
AN3826 0.024
AN2913 >10,000
Fig. 3. Docking model of AN4800 (green) at the active site of PDE4B catalytic
domain. Color code: blue for protein carbon and cyan for ligand carbon atoms, red
for oxygen, and dark blue for nitrogen atoms.
Table 2
Inhibition of proinﬂammatory, TH1 and TH2 cytokines by AN2728, AN2898, AN2913, AN4800 and AN3826 in human peripheral blood mononuclear cells. Rolipram was used as a
comparator and Dexamethasone as the positive control.
Compound IC50 (lM)
Proinﬂammatorya TH1b TH2b
TNF-a IL-1b IL-2 IFN-c IL-4 IL-5 IL-10
AN2728 0.50 (5, 1.6) >100 (5) 0.59 (6, 1.26) 0.72 (6, 1.86) >10 (5) 2.25 (5, 1.42) 2.58 (5, 3.46)
AN2898 0.14 (5, 1.86) >100 (5) 0.17 (5, 1.29) 0.17 (5, 2.26) >10 (5) 0.25 (5, 1.37) 0.92 (5, 3.3)
AN2913 23.7 (3, 2.4) >100 (3) 61.12 (3, 1.58) 16.12 (3, 1.09) 48.99 (2, 1.34) >100 (3) 69.69 (2, 1.06)
AN4800 0.00084 (4, 2.41) >10 (4) 0.00068 (4, 2.41) 0.000503 (4, 3.16) 3.97 (3, 1.48) NT NT
AN3826 0.0086 (3, 3.64) >100 (3) 0.0053 (3, 2.43) 0.013 (3, 2.05) 1.99 (2, 1.61) NT 0.231 (3, 3.77)
Rolipram 0.15 (2, 1.05) >100 (2) 0.22 (4, 1.44) 0.22 (4, 1.36) >10 (3) 0.46 (3, 1.66) 0.78 (4, 1.62)
Dexamethasone 0.009 (3, 1.28) 0.0084 (3, 1.77) 0.0085 (3, 3.1) 0.0077 (3, 2.48) 0.029 (3, 3.21) 0.0069 (3, 2.13) 0.00045 (3, 2.44)
a 1 lg/ml LPS, 24 h.
b 20 ng/ml PHA, 24 h for TH1 and 48 h for TH2. Geometric means of IC50 values are presented. Numbers in parentheses represent number of experiments averaged and the
fold variation around the geometric mean (geometric standard deviation). In each experiment, each concentration was tested in triplicate.
Table 3
Percent inhibition of phosphodiesterase enzymes at 10 lM (IC50 in lM) by AN2728, AN2898 and AN4800.
PDE1A PDE2A PDE3A PDE4 PDE5 PDE6 PDE7A PDE8A PDE9A1 PDE10 (cAMP) PDE11
(cAMP)
AN2728 70.7 (6.12) 42.9 72.2 (6.41) 99.9 (0.11) 32.0 7.6 90.5 (0.73) 51.4 0 50.4 57.2
Selectivity vs. PDE4 56 58 7
AN2898 85.4 (1.70) 67.9 (9.8) 65.5 (4.12) 99.8 (0.027) 25.1 25 88.1 (0.21) 72.0 0 57.4 66.6
Selectivity vs. PDE4 63 363 153 8
AN4800 NT NT 74 (3.2) 100 (0.0013) 82 (1.3) 79 (1.1) 100 (0.0057) 70 (2.1) NT 51 56
Selectivity vs. PDE4 2462 1000 4.4 1615
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compound AN3826, with a 2-hydroxyethoxy group which would
only partially ﬁll in the hydrophobic pocket. AN3826 had an IC50
of 24 nM against PDE4, 3-fold better than that of AN2898, however
30-fold less potent than that of AN4800.
To determine whether the increase in AN4800 potency was
accompanied by a loss of speciﬁcity for PDE4 over other PDE en-
zymes, AN4800 was tested against a panel of PDE enzymes (Table
3). No substantial differences in speciﬁcity were observed for
AN4800 compared to the less potent oxaboroles, demonstrating
that extending the molecule into the adenine pocket did not affect
speciﬁcity.
3.4. The phenoxybenzoxaboroles show inhibitory activity against pro-
inﬂammatory, TH1 and TH2 cytokines
Phenoxybenzoxaboroles, and comparator cytokine inhibitors
were tested for their ability to inhibit production of TNF-a, IL-1b,
IL-2, IFN-c, IL-4, IL-5 and IL-10. AN2728 showed submicromolar
activity against TNF-a, IL-2 and IFN-c, with single digit micromolar
IC50 values against IL-5 and IL-10 (Table 2). AN2898 was approxi-
mately 5- to 8-fold more potent than AN2728, inhibiting most of
these cytokines at submicromolar concentrations. Neither com-
pound inhibited IL-1b or IL-4, an observation which was also made
for Rolipram. AN2913, identical in structure to AN2728 but with a
carbon atom replacing the boron, showed no ability to inhibit cyto-
kines, demonstrating the essentiality of boron for inhibition.
AN4800 showed signiﬁcantly more potency than AN2898 against
TNF-a, IL-2 and IFN-c (166- to 337-fold). AN4800 and AN3826
both inhibited IL-4 with low micromolar IC50s.4. Discussion
The phenoxybenzoxaboroles are a novel class of compounds
containing a boron atom incorporated into a fused ring system.We have demonstrated that these molecules have the ability to
bind the activated water and the bimetal ions in the catalytic site
of PDE4B, inhibiting enzyme activity and functionally resulting in
inhibition of cytokine production in mammalian cells.
The boron atom takes either a trigonal planar or a tetrahedral
conﬁguration, depending on the pH of its environment and the
pKa of the particular compound. The crystal structure of AN2898
in the catalytic site of PDE4B shows that the boron in the tetrahe-
dral conformation overlaps the phosphate of cAMP at the bimetal
site. In this mode, boron acts as a unique mimic of the phosphate
of the cAMP. Thus, the hydrated boron is a transition state mimetic.
Replacement of the oxaborole ring with a lactol ring, as in AN2913,
results in signiﬁcant loss of enzyme and cytokine inhibitory activ-
ity (Fig. 3, Table 2), providing additional evidence for the essential-
ity of boron and the preference for tetrahedral geometry with a
negative charge. Binding of the phenoxybenzoxaboroles to the bi-
metal active site is fundamentally different from binding of the
catechol-based PDE4 inhibitors, Rolipram and Roﬂumilast, to the
hydrophobic adenine pocket without interacting with the bimetal
center. Phenoxybenzoxaboroles which extend into the adenine
pocket, for example AN4800, have PDE4 inhibitory potency, and
functional activity that are enhanced between 150- and 300-fold
over those of AN2898. When an alcohol, rather than an ester,
was installed, as in AN3826, the potency against PDE4 and cyto-
kines was intermediate between potencies of AN2898 and
AN4800. As suggested by one of the possible binding modes of
AN3826 from our docking analysis, the 2-hydroxyethoxy group
maintains the H-bond with Gln 443 but falls short ﬁlling the rest
of the hydrophobic pocket.
Kleinman et al. demonstrated that by incorporating structural
features of cAMP and a site for metal coordination (a hydroxymate
moiety) within the Rolipram pharmacophore, more potent PDE4
inhibitors could be obtained [9]. This dual binding to the bimetal
center with extension of the molecules into the adenine pocket
substantially increases potency, as demonstrated by the pheno-
xybenzoxaboroles. The hydroxamate moiety has non-speciﬁc me-
3414 Y.R. Freund et al. / FEBS Letters 586 (2012) 3410–3414tal chelating [10] features that make it undesirable for use as a
drug. The phenoxybenzoxyboroles take advantage of the same
interaction, but are better suited for use as drugs, exhibiting good
pharmacokinetics and reduced toxicity potential.
Binding to the bimetal center does not confer selectivity for
PDE4 although the phenoxybenzoxaboroles show 4- to >2000-fold
lower IC50 values for PDE4 than for other PDE enzymes. AN4800,
with increased potency, maintained the same selectivity proﬁle.
The phenoxybenzoxazoles showed the least selectivity for PDE4
when compared to PDE7. Wang et al. [10] have compared Rolipram
in the catalytic sites of PDE4 and PDE7, based on the crystal struc-
tures, and demonstrated that the cyclopentanyl ring of Rolipram
clashes with the side chain of Ile-412 on PDE7, allowing selective
binding of Rolipram to the PDE4 catalytic site compared to the
PDE7 site. Extrapolating from the PDE4 modeling of AN4800 to
PDE7, AN4800 would not be expected to contact the Ile-412. If
AN4800 selectivity for PDE4 were to be further optimized, the mol-
ecule could be extended toward the area of the PDE7 Ile-412. This
would be predicted to detrimentally affect binding to PDE7 but not
to PDE4.
Phosphodiesterases play an important role in regulating im-
mune responsiveness by providing the mechanism for removal of
cAMP. Inhibiting PDE4 allows accumulation of cAMP with concom-
itant activation of protein kinase A (PKA) and a resulting inhibition
of pro-inﬂammatory and T cell cytokines [11]. Phenoxybenzoxabo-
roles, as well as catachols, inhibited LPS-stimulated TNF-a produc-
tion and the T cell-mediated cytokines, IFN-c and IL-2, to
submicromolar (AN2728, AN2898 and Rolipram) and subnanomo-
lar (AN4800) IC50 values. These compounds do show selectivity in
cytokine inhibition patterns; like Rolipram, they do not inhibit IL-
1b and the less potent phenoxybenzoxaboroles do not inhibit IL-4.
PDE4 inhibitors have been extensively studied as anti-inﬂam-
matory compounds [12,13], since excessive cytokine production
contributes to the pathogenesis of numerous inﬂammatory and
autoimmune diseases [14]. Thus an oral or topically-bioavailable
small molecule capable of suppressing multiple critical cytokines,
without the side-effects of the catechol inhibitors, would be an
attractive option for these diseases. AN2728 has been proven safe
and efﬁcacious for topical treatment of mild-to-moderate psoriasis,
having successfully completed three Phase 1b and four Phase 2
clinical trials. With the understanding of phenoxybenzoxaborole
binding to the bimetal center of the PDE4 catalytic site and the
demonstrated gain of interactions in the adenine pocket, there is
now the possibility of generating much more potent PDE4 inhibi-
tors which are distinct from the catechol class and have utility
against immune-mediated pathologies.Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.febslet.
2012.07.058.
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